Tashkent, Uzbekistan (UzDaily.com) -- The Uzbek group of companies Eriell and the Turkish companies Abdi Ibrahim and Guray Group signed a trilateral protocol on cooperation in the production, sale, marketing and distribution of licensed Abdi İbrahim medicines in Uzbekistan.

The protocol, signed during last week’s Tashkent International Investment Forum, reflects the three companies’ intentions to create a joint venture in Tashkent. 

The parties intend to organize the production of medicines in order to minimize import and provision of high-quality drugs to the population of the republic. On the part of the Turkish companies, the protocol was signed by Gürel Aydin, Chairman of the Board of Guray Group and Suha Taspolatoğlu, General Director of Abdi Ibrahim.

On the Uzbek side, the protocol was signed by Bakhtiyor Fazylov, founder of Eriell. At the signing of the document, he stated: “In the state social policy, ensuring the health of the population of Uzbekistan is given a leading role. This means the production of modern pharmaceuticals directly in the country, providing them to the domestic market and our citizens, which is an important and urgent task. I am pleased that our partnership will be able to contribute to the realization of this significant goal.”

The parties also plan to build a pharmaceutical plant that meets the requirements of good manufacturing practice (GMP), organize the production and quality control of medicines. The total investment will be approximately US$100 million and will take five years to complete.